Enzymatically Transformable Polymersome-Based Nanotherapeutics to Eliminate Minimal Relapsable Cancer

Enzymatically Transformable Polymersome-Based Nanotherapeutics to Eliminate Minimal Relapsable Cancer

© 2021 Wiley-VCH GmbH.

Détails bibliographiques
Publié dans:Advanced materials (Deerfield Beach, Fla.). - 1998. - 33(2021), 49 vom: 01. Dez., Seite e2105254
Auteur principal: Li, Junjie (Auteur)
Autres auteurs: Ge, Zhishen, Toh, Kazuko, Liu, Xueying, Dirisala, Anjaneyulu, Ke, Wendong, Wen, Panyue, Zhou, Hang, Wang, Zheng, Xiao, Shiyan, Van Guyse, Joachim F R, Tockary, Theofilus A, Xie, Jinbing, Gonzalez-Carter, Daniel, Kinoh, Hiroaki, Uchida, Satoshi, Anraku, Yasutaka, Kataoka, Kazunori
Format: Article en ligne
Langue:English
Publié: 2021
Accès à la collection:Advanced materials (Deerfield Beach, Fla.)
Sujets:Journal Article bioavailability and toxicity inflammatory microenvironment minimal residual diseases postsurgical wounds premetastatic niche stimuli-responsive nanotherapeutics Matrix Metalloproteinase Inhibitors Colchicine SML2Y3J35T
LEADER 01000caa a22002652c 4500
001 NLM331635054
003 DE-627
005 20250302134618.0
007 cr uuu---uuuuu
008 231225s2021 xx |||||o 00| ||eng c
024 7 |a 10.1002/adma.202105254  |2 doi 
028 5 2 |a pubmed25n1105.xml 
035 |a (DE-627)NLM331635054 
035 |a (NLM)34622509 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a eng 
100 1 |a Li, Junjie  |e verfasserin  |4 aut 
245 1 0 |a Enzymatically Transformable Polymersome-Based Nanotherapeutics to Eliminate Minimal Relapsable Cancer 
264 1 |c 2021 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 23.05.2022 
500 |a Date Revised 31.05.2022 
500 |a published: Print-Electronic 
500 |a Citation Status MEDLINE 
520 |a © 2021 Wiley-VCH GmbH. 
520 |a Prevention of metastatic and local-regional recurrence of cancer after surgery remains difficult. Targeting postsurgical premetastatic niche and microresiduals presents an excellent prospective opportunity but is often challenged by poor therapeutic delivery into minimal residual tumors. Here, an enzymatically transformable polymer-based nanotherapeutic approach is presented that exploits matrix metalloproteinase (MMP) overactivation in tumor-associated tissues to guide the codelivery of colchicine (microtubule-disrupting and anti-inflammatory agent) and marimastat (MMP inhibitor). The dePEGylation of polymersomes catalyzed by MMPs not only exposes the guanidine moiety to improve tissue/cell-targeting/retention to increase bioavailability, but also differentially releases marimastat and colchicine to engage their extracellular (MMPs) and intracellular (microtubules) targets of action, respectively. In primary tumors/overt metastases, the vasculature-specific targeting of nanotherapeutics can function synchronously with the enhanced permeability and retention effect to deter malignant progression of metastatic breast cancer. After the surgical removal of large primary tumors, nanotherapeutic agents are localized in the premetastatic niche and at the site of the postsurgical wound, disrupting the premetastatic microenvironment and eliminating microresiduals, which radically reduces metastatic and local-regional recurrence. The findings suggest that nanotherapeutics can safely widen the therapeutic window to resuscitate colchicine and MMP inhibitors for other inflammatory disorders 
650 4 |a Journal Article 
650 4 |a bioavailability and toxicity 
650 4 |a inflammatory microenvironment 
650 4 |a minimal residual diseases 
650 4 |a postsurgical wounds 
650 4 |a premetastatic niche 
650 4 |a stimuli-responsive nanotherapeutics 
650 7 |a Matrix Metalloproteinase Inhibitors  |2 NLM 
650 7 |a Colchicine  |2 NLM 
650 7 |a SML2Y3J35T  |2 NLM 
700 1 |a Ge, Zhishen  |e verfasserin  |4 aut 
700 1 |a Toh, Kazuko  |e verfasserin  |4 aut 
700 1 |a Liu, Xueying  |e verfasserin  |4 aut 
700 1 |a Dirisala, Anjaneyulu  |e verfasserin  |4 aut 
700 1 |a Ke, Wendong  |e verfasserin  |4 aut 
700 1 |a Wen, Panyue  |e verfasserin  |4 aut 
700 1 |a Zhou, Hang  |e verfasserin  |4 aut 
700 1 |a Wang, Zheng  |e verfasserin  |4 aut 
700 1 |a Xiao, Shiyan  |e verfasserin  |4 aut 
700 1 |a Van Guyse, Joachim F R  |e verfasserin  |4 aut 
700 1 |a Tockary, Theofilus A  |e verfasserin  |4 aut 
700 1 |a Xie, Jinbing  |e verfasserin  |4 aut 
700 1 |a Gonzalez-Carter, Daniel  |e verfasserin  |4 aut 
700 1 |a Kinoh, Hiroaki  |e verfasserin  |4 aut 
700 1 |a Uchida, Satoshi  |e verfasserin  |4 aut 
700 1 |a Anraku, Yasutaka  |e verfasserin  |4 aut 
700 1 |a Kataoka, Kazunori  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Advanced materials (Deerfield Beach, Fla.)  |d 1998  |g 33(2021), 49 vom: 01. Dez., Seite e2105254  |w (DE-627)NLM098206397  |x 1521-4095  |7 nnas 
773 1 8 |g volume:33  |g year:2021  |g number:49  |g day:01  |g month:12  |g pages:e2105254 
856 4 0 |u http://dx.doi.org/10.1002/adma.202105254  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_350 
951 |a AR 
952 |d 33  |j 2021  |e 49  |b 01  |c 12  |h e2105254